Abbott Laboratories (ABT) is now in the Undervalued zone, suggesting that its current forward PE ratio of 22.44 is considered Undervalued compared with the five-year average of 24.66. The fair price of Abbott Laboratories (ABT) is between 126.13 to 144.39 according to relative valuation method. Compared to the current price of 114.59 USD , Abbott Laboratories By Undervalued By 9.15%.

Relative Value

Fair Zone

126.13-144.39

Current Price：114.59

9.15%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Abbott Laboratories (ABT) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Abbott Laboratories (ABT) has a current Price-to-Book (P/B) ratio of 4.24. Compared to its 3-year average P/B ratio of 4.80, the current P/B ratio is approximately -11.79% higher. Relative to its 5-year average P/B ratio of 5.23, the current P/B ratio is about -19.04% higher. Abbott Laboratories (ABT) has a Forward Free Cash Flow (FCF) yield of approximately 3.20%. Compared to its 3-year average FCF yield of 2.78%, the current FCF yield is approximately 15.10% lower. Relative to its 5-year average FCF yield of 3.33%, the current FCF yield is about -3.93% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for ABT competitors is 7.06, providing a benchmark for relative valuation. Abbott Laboratories Corp (ABT.N) exhibits a P/S ratio of 4.57, which is -35.23% above the industry average. Given its robust revenue growth of 4.42%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of ABT increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of ABT in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is ABT currently overvalued or undervalued?

What is Abbott Laboratories (ABT) fair value?

ABT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Abbott Laboratories (ABT) is between 126.13 to 144.39 according to relative valuation method.

How does ABT's valuation metrics compare to the industry average?

The average P/S ratio for ABT's competitors is 7.06, providing a benchmark for relative valuation. Abbott Laboratories Corp (ABT) exhibits a P/S ratio of 4.57, which is -35.23% above the industry average. Given its robust revenue growth of 4.42%, this premium appears unsustainable.

What is the current P/B ratio for Abbott Laboratories (ABT) as of Mar 02 2026?

As of Mar 02 2026, Abbott Laboratories (ABT) has a P/B ratio of 4.24. This indicates that the market values ABT at 4.24 times its book value.

What is the current FCF Yield for Abbott Laboratories (ABT) as of Mar 02 2026?

As of Mar 02 2026, Abbott Laboratories (ABT) has a FCF Yield of 3.20%. This means that for every dollar of Abbott Laboratories's market capitalization, the company generates 3.20 cents in free cash flow.

What is the current Forward P/E ratio for Abbott Laboratories (ABT) as of Mar 02 2026?

As of Mar 02 2026, Abbott Laboratories (ABT) has a Forward P/E ratio of 22.44. This means the market is willing to pay $22.44 for every dollar of Abbott Laboratories's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Abbott Laboratories (ABT) as of Mar 02 2026?

As of Mar 02 2026, Abbott Laboratories (ABT) has a Forward P/S ratio of 4.57. This means the market is valuing ABT at $4.57 for every dollar of expected revenue over the next 12 months.

ABT Valuation